Fundraising FoxWellington Management — 2017 Investments
3 investments dated 2017 · listed companies and verified rows first · show all
Gilead discovers, develops, and delivers therapeutic medicines for life-threatening diseases, with focus on virology, oncology, and inflammation across 35+ countries.
BiotechHealthtechMedical DevicesPalo Alto, US
Ravindra Majeti(Director)Irving Weissman(Director)Eric Jensen(Executive Officer)
BoardChristopher Schaepe(Director)inJeffrey Bird(Director)Dennis Henner(Director)
Co-investorsBluebird VenturesGV (Google Ventures)Lightspeed Venture PartnersSofinnova VenturesClarus VenturesSutter Hill Ventures
PMV Pharma is a precision oncology company developing therapies that selectively target mutant p53 to treat cancers whose tumors carry p53 gene mutations.
BiotechHealthtechLongevityCranbury, US
David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Co-Founder & Member, Scientific Advisory Board)David H. Mack(Co-Founder, President & CEO)Thomas Shenk(Co-Founder)Deepika Jalota(Chief Development Officer)
Co-investorsAvoro Capital AdvisorsNextech InvestOUP (Osage University Partners)RA CapitalViking GlobalOrbiMed
Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Keith Gottesdiener(Executive Officer, Director)inBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in
BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inNeil Exter(Director)in
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)Pfizer Venture InvestmentsOrbiMedThird Rock Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.